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Abstract
Background: The association of human papillomavirus (HPV) types to neoplastic lesions increase as a function of
their oncogenicity and the duration of the infection since lesion severity progresses from low-grade to high-grade
and cancer. In an outbreak, the prevalence of the HPV type involved would increase and the proportion of the
associated low-grade lesions would predominate over severe lesions. In this study, the prevalence of HPV types and
their association to neoplastic lesions was determined in women subjected to colposcopy in San Luis Potosí,
Mexico.
Methods: DNA from high-risk (HR) and low-risk (LR) HPV types was identified by E6 nested multiplex PCR in
cervical scrapes from 700 women with normal cytology, atypical squamous cells of undetermined significance
(ASCUS), low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) or
invasive cervical cancer (CC).
Results: Overall HPV-DNA prevalence was 67.7 %, that of HR-HPV was 63.1 %, and that of LR-HPV was 21.3 %. The
highest prevalence (78.2 %) occurred in the 15–24 year group, whereas that of single infections was 52 % and that
of multiple infections (i.e., by 2–6 HPV types) was 48 %. The most prevalent HR types were HPV33 (33.1 %), HPV16
(16.6 %), HPV18 and HPV51 (6.7 % each). HR-HPV prevalence was 29.6 % in normal cytology, 26.7 % in ASCUS,
63.3 % in LSIL, 68.2 % in HSIL, and 90.5 % in CC. Three prevalence trends for HR-HPV types were found in neoplastic
lesions of increasing severity: increasing (LSIL < HSIL < CC) for HPV16, HPV39, HPV18, HPV58, HPV31 and HPV35;
asymptotic (LSIL < HSIL ≈ CC) for HPV51 and HPV68; U-shaped (LSIL < HSIL > CC) for HPV33.
Conclusions: Two-thirds of the women subjected to colposcopy from 2007 to 2010 in San Luis Potosí have HPV
infections which predominate in the 15–24 years group. Around half of the infections are by one viral type and the
rest by 2–6 types. HPV33 is the most prevalent type, followed by HPV16. Overall HR-HPV prevalence increases with
the severity of neoplastic lesions. HPV33 prevalence is highest in LSIL and its U-shaped trend with progressing
neoplastic lesions differs from the growing/asymptotic trends of other HR-HPV types. An ongoing or recent HPV33
outbreak is consistent with its high prevalence and anomalous association to LSIL.
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Background
Cervical cancer (CC) is the second cause of death by
cancer among Mexican women [1]. In Mexico, 4031
deaths due to CC were reported in 2008 and the mortal-
ity rate was 9.7 per 100,000 women [2], around three
times higher than that in developed countries [3]. In the
Mexican state of San Luis Potosí, where this study was
conducted, the CC mortality rate in 2008 was 9.3 per
100,000 women, similar to the national mortality rate [2].
Persistent infection of the cervical epithelium by ano-
genital human papillomavirus (HPV) types induces
neoplastic lesions that may progress to invasive cancer
[4, 5]. Among the 40 anogenital HPV types, the low-risk
(LR-HPV) ones are associated to benign tumors and the
high-risk (HR-HPV) ones to CC [6]. Two high-risk
types, HPV16 and HPV18, cause around 70 % of CC
cases worldwide [7] whereas two low-risk types, HPV6
and HPV11, cause 95 % of the anogenital wart cases [8].
The prevalence of HPV types infecting the cervix
serves to predict the efficacy of the vaccines that prevent
both HPV infections and cervical neoplastic lesions [9].
Although the prevalence of specific HPV types varies
with the geographic region and the severity of neo-
plastic lesions [9–11], international meta-analyses
show that HPV16 and HPV18 are the most prevalent
high-risk types associated to cervical neoplastic lesions
and CC [12, 13].
A previous study of our group on cervical infections
by HR-HPV types in women from the capital city of San
Luis Potosí demonstrated that HPV16 had the highest
prevalence, 59 times that of HPV33 [14]. The present
study identified 13 HR-HPV and six LR-HPV types in
cervical scrapes of women from the six state sanitary ju-
risdictions that were subjected to colposcopy between
2007 and 2010. HPV infections were found in two-thirds
of them, with three times more HR-HPV than LR-HPV
types. The predominant type was HPV33, whose preva-
lence doubled that of HPV16, the second most prevalent
type. The association of all HR-HPV types to neoplastic
lesions increased as a function of their severity, except
for HPV33, whose prevalence was highest in LSIL. An
ongoing HPV33 outbreak is consistent with its high




This cross-sectional study of women attending the five
colposcopy clinics of the state of San Luis Potosí was ap-
proved by the Ethics and Research Committee of the
State Health Services. Informed consent from each
participant included her authorization for colposcopy,
cervical scraping and biopsy sampling, HPV DNA detec-
tion and genotyping and the use of clinical and
sociodemographic data. Personal data of the participants
are strictly confidential. The official Mexican guidelines
for cervical cancer prevention, diagnosis, treatment, con-
trol and surveillance are mandatory at all Mexican hos-
pitals and authorize health personnel to take samples
both for cervical cytology and HPV infection tests to any
sexually active woman less than 18 years old who requests
them. Women are referred to colposcopy if a cervical
anomalous result is diagnosed through gynecological
examination or cytology; HPV tests are offered to women
subjected to colposcopy and may be performed through
hybrid capture or PCR.
Setting
Recruitment was based on the availability of sociodemo-
graphic and clinical data, and of the cervical cytological
and histopathological diagnoses of the women attending
the clinics located at the Health Center of the capital
city, the general hospitals of Matehuala, Rioverde, and
Ciudad Valles, and the Tamazunchale Community Hos-
pital, between June 2007 and August 2010.
Participants
Eight hundred and thirty-seven 15–85 years-old women
were eligible for the study. Those with incomplete or
missing clinical records, inadequate conditions for cer-
vical scraping (menstruation, pregnancy), or refusing to
participate were excluded. Those with complete records,
cytologic diagnosis before colposcopy, histopathologic
diagnosis after colposcopy and informed consent were
included.
Variables
The variables analyzed were age at the time of the cervical
scraping, prevalence of the HPV types identified and the
cytologic and histopathologic diagnoses formulated with
the 2001 Bethesda System [15]: normal, atypical squamous
cells of undetermined significance (ASCUS), low-grade
squamous intraepithelial lesions (LSIL), high-grade squa-
mous intraepithelial lesions (HSIL) and cervical cancer
(CC). “Normal” diagnosis corresponded to women seen
for the first time or followed up. Histopathologic diagno-
ses of cervical intraepithelial neoplasia (CIN), formulated
with Richart [16] nomenclature were reclassified as fol-
lows: CIN1 as LSIL, CIN2/CIN3 as HSIL [15]. Prevalence
of each DNA HPV type was correlated with the severity of
cervical neoplastic lesions.
Sample size
The minimum size of a significant random sample
(n = 682 cases), calculated with the OpenEpi 2.3.1
software [17], was based on the 1080 CIN and CC
cases recorded during 2006 in the state of San Luis
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Potosí [2] assuming 50 % HPV prevalence, a 99 %
confidence interval and a 3 % error.
Cervical scrapes
From every woman an expert gynecologist took a cer-
vical scrape for cytology, and less than two months later
another one for the HPV test that was immediately
placed in a tube containing 2 mL of fixative (1 mL of
phosphate buffered saline supplemented with ethylenedi-
amine tetraacetate and 1 mL of 96 % ethanol). Fixed
scrapes were short term stored, transported at room
temperature and maintained in the laboratory at 4 °C
until DNA was extracted [14].
DNA extraction and quantification
Each fixed sample was centrifuged at 13,000 rpm
(16,250 × g) for 5 min in a Mikro 20 centrifuge (Hettich,
Cologne, Germany). The supernatant was discarded and
to the pellet were added 500 μL of TES (10 mM Tris-
HCl, 2 mM EDTA, 0.4 M NaCl, pH 8.0), 50 μL of 10 %
SDS and 20 μL of proteinase K (20 mg/mL). The mix-
tures were incubated 3 h at 56 °C in a thermoblock to
digest proteins. After this incubation, 151 μL of 5 M
NaCl were added and each mixture was centrifuged
15 min at 16,250 × g. The supernatant was carefully aspi-
rated, transferred to a new tube to which 577 μL of
isopropanol at −20 °C were added, and allowed to stand
10 min at 4 °C to precipitate the DNA. The tube was
centrifuged at 16,250 × g for 10 min and the supernatant
discarded by decantation [14].
The DNA pellet was washed twice with 1 mL of 70 %
ethanol at room temperature and centrifuged 1 min at
10,000 rpm (9615 × g). The supernatant was carefully
discarded by decantation and the pellet allowed to dry at
room temperature for 15 min with the tube inverted on
a paper towel. Pelleted DNA was dissolved with 50 or
100 μL of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)
and 2 μL were applied to the Epoch Micro-Volume Spec-
trophotometer System (BioTek Instruments, Winooski,
VT, USA) to determine optical densities at 260 and
280 nm.
HPV detection and genotyping
The procedure was performed in 25 μL mixtures using
the nested multiplex PCR E6 gene amplification method
of Sotlar et al. [18], which identifies 13 HR-HPV types
and six LR-HPV types but does not differentiate HPV6
from HPV11. Genotyping is based on the size of the
amplicons of the identifiable HPV types. Initial PCR
mixtures contained the GPE6/E7 consensus oligonucleo-
tides purchased from Integrated DNA Technologies
(Coralville, IA, USA) which amplify a ~630 bp product
from E6 viral genes. Nested PCR was carried out in four
separate mixtures, each containing 1/25 volume of the
initial PCR mixture and cocktails of type-specific nested
oligonucleotide pairs, also purchased from Integrated
DNA Technologies. To avoid contamination, aliquots of
each reagent were kept and managed separately and
each stage of the HPV test —DNA extraction, PCR, and
electrophoresis— was performed by operators using new
gloves in separate laboratory areas that were decontami-
nated each time after a group of samples had been
processed.
The initial mixtures contained PCR buffer (50 mM
KCl, 20 mM Tris-HCl, pH 8.3), 200 μM dNTPs (each of
the four), 1.5 mM MgCl2, 0.3 μM GPE6/E7 consensus
oligonucleotides (each) and 1 unit of Taq DNA polymer-
ase (Invitrogen, Carlsbad, CA, USA). Nested PCR mix-
tures contained PCR buffer, 152 μM dNTPs, 2 mM
MgCl2, 0.3 μM HPV-type-specific oligonucleotides
(each) and 1 unit of Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA). PCR mixtures for β-globin con-
tained 0.3 μM PC04/GH20 oligonucleotides and the
same final concentrations of PCR buffer, dNTPs, and
Taq DNA polymerase as in nested PCR. Amplification
of the 260 bp segment of the human β-globin gene
served to assess the quality of DNA in the HPV-
negative cases [19].
The four nested PCR mixtures contained a total of 18
oligonucleotide pairs specific for 13 HR-HPV types
(HPV16, HPV18, HPV31, HPV33, HPV35, HPV39,
HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and
HPV68) and six BR-HPV types (HPV6/11, HPV42,
HPV43, HPV44 and HPV66). Mixtures without DNA
were used as negative controls, whereas mixtures with
DNA of the SiHa cell line (transformed by HPV16),
DNA of the HeLa cell line (transformed by HPV18) or
the pHPV33 plasmid containing the complete HPV33
genome were used as positive controls.
Incubations were performed in a 2720 thermocycler
(Applied Biosystems, Foster City, CA, USA) under the
following conditions. Starting PCR mixtures: initial de-
naturation at 94 °C for 4 min; 40 cycles at 94 °C for
1 min, 40 °C for 1 min and 72 °C for 2 min and a final
extension at 72 °C for 10 min. Nested and β-globin PCR
mixtures: initial denaturation at 94 °C for 4 min; 35 cy-
cles at 94 °C for 30 s, 56 °C for 30 s, 72 °C for 45 s and a
final extension at 72 °C for 4 min.
Five-μL of nested or β-globin PCR mixtures were ap-
plied to SB-2 % agarose [20] 5-mm thick gels run at
120 V for 35 min, stained with ethidium bromide and
visualized under ultraviolet light in a ChemiDoc photo-
documentation system (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Was performed with the Epi Info 7.1.1.14 software [21].
Age was expressed as the mean and standard deviation
(SD) and as a categorical variable (age groups: 15–24,
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25–34, 35–44, 45–54 and ≥55 years). The grades of neo-
plastic lesions were treated as absolute measures or pro-
portions. HPV DNA prevalence (overall, of HR-HPV
types, of LR-HPV types and of each of the HPV types
identified in single and multiple infections) were calcu-
lated with 95 % confidence intervals (CI). Prevalences of
single and multiple HPV types were calculated inde-
pendently. HPV DNA categories: general, HR-HPV
types, LR-HPV, single and multiple infections, were
stratified by age groups (15–24, 25–34, 35–44, 45–54
and ≥55 years) and the prevalence in each group calcu-
lated with 95 % CI. The same HPV DNA categories were
also stratified by the severity of neoplastic lesions, and
the prevalence of groups with normal, ASCUS, LSIL,
HSIL and CC diagnoses were calculated with 95 % CI.
Single and multiple infections were stratified by the se-
verity of neoplastic lesions and the corresponding preva-
lence calculated for each lesion group.
Results
Sociodemographic and clinical features of the
participants
The 837 women subjected to colposcopy were assessed
for recruitment. Seventy were excluded for having in-
complete or no medical records. Among the 767 women
recruited and allocated to HPV diagnosis, 67 were ex-
cluded for having unidentified cervical scrapes (n = 31)
or DNA of insufficient quality (n = 36) (Fig. 1).
The study included the remaining 700 women 15 to
82 years old (mean age ± SD = 37.4 ± 12.0 years) with the
following diagnoses: normal cytology (n = 27, 3.9 %),
ASCUS (n = 15, 2.1 %), LSIL (n = 489, 69.9 %), HSIL
(n = 148, 21.1 %) and CC (n = 21, 3.0 %) (Additional
file 1: Table S1).
Overall, HR- and LR-HPV DNA prevalence
Overall HPV DNA prevalence was 67.6 %, with 52.0 %
of the cases having a single viral type (“single infection”)
and 48.0 % having multiple viral types (“multiple
infection”). HR-HPV DNA prevalence was 63.1 %, and
LR-HPV DNA prevalence was 21.3 % (Additional file 1:
Table S1).
The most prevalent HR-HPV types were, in descend-
ing order, HPV33 (33.1 %), HPV16 (16.6 %), HPV18
(6.7 %) and HPV51 (6.7 %). The most prevalent LR-HPV
types were HPV6/11 (8.3 %), HPV43 (7.9 %) and HPV66
(5.3 %) (Fig. 2, Additional file 1: Table S1).
The highest overall HPV DNA prevalence (78.2 %) oc-
curred in the 15–24 years group; decreased to 67.4 and
62.8 % in the 25–34 and 35–44 years groups, respect-
ively; increased slightly to 65.8 %) in the 45–54 years
group and to 69.1 % in the ≥55 years group (Fig. 3,
Additional file 1: Table S2).
The highest HR-HPV DNA prevalence (72.3 %) oc-
curred in the 15–24 years group, decreased to 65.6 % in
the 25–34 years group and was slightly lower and similar
in the groups of 35–44, 45–54 and ≥55 years groups
Fig. 1 Flow diagram of the study
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(59.3, 59.8 and 58.8 %, respectively) (Fig. 3, Additional
file 1: Table S2).
The highest LR-HPV DNA prevalence (29.7 %) corre-
sponded to the 15–24 years group, decreased to 21.4 %
in the 25–34 years group, was maintained in the 35–
44 years group (21.6 %), reached its minimum value in
the 45–54 years group (14.5 %) and increased slightly to
19.1 % in the ≥55 years group (Fig. 3, Additional file 1:
Table S2).
The most prevalent HR-HPV type in all age groups
was HPV33, followed by HPV16. The third most preva-
lent type varied with age: HPV56 in the 15–24 years
group, HPV51 in 25–34 years group HPV52 in 35–
44 years group, HPV18 in 45–54 years group, HPV68 in
the ≥55 years group (Additional file 1: Table S2).
HPV33 prevalence was similar in the 15–24 years
(35.6 %) and 25–34 years (35.3 %) groups, decreased in
the 35–44 years group (28.6 %), was highest in the
45–54 years group (38.5 %), and decreased in the ≥ 55 years
group (26.5 %). In contrast to HPV33 prevalence, the
highest HPV16 prevalence (20.8 %) occurred in the
15–24 years group, was slightly lower but similar in
the 25–34 and 35–44 years groups (16.8 % and 18.1 %, re-
spectively), decreased to 8.5 % in the 45–55 years group,
and increased in the ≥55 years group (20.6 %) to a value
similar to that of the 15–24 years group (Additional file 1:
Table S2).
Overall, HR- and LR-HPV DNA prevalence in neoplastic
lesions
Overall HPV DNA prevalence was 29.6 % in cases with
normal cytology, 53.3 % in ASCUS, 67.7 % in LSIL,
72.3 % in HSIL and 90.5 % in CC (Fig. 4, Additional
file 1: Table S3).
Fig. 2 Prevalence of HR-HPV and LR-HPV types. The prevalence values of HR-HPV types (red bars) and LR-HPV types (blue bars) are presented in
descending order
Fig. 3 HPV DNA prevalences by age groups: overall, HR-HPV types and LR-HPV types. The overall HPV prevalence trend has a slightly pronounced
U shape with its highest value in the 15–24 years group (78.2 %), followed by that of the ≥55 years group (69.1 %)
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HR-HPV DNA prevalence was close to the overall
HPV DNA prevalence found in lesions of increasing se-
verity, except for ASCUS (29.6 % in cases with normal
cytology, 26.7 % in ASCUS), 63.4 % in LSIL, 68.2 % in
HSIL and 90.5 % in CC. In contrast, LR-HPV DNA
prevalence was only 7.4 % in cases with normal cytology
and increased to 26.7 and 28.6 % in ASCUS and CC
(Fig. 4, Additional file 1: Table S3).
Prevalence of a single HPV DNA type was highest in
ASCUS (53.3 %), clearly lower in cases with normal cy-
tology (14.8 %), and intermediate and similar in LSIL,
HSIL and CC (36.4, 33.1 and 33.3 %, respectively) (Fig. 5,
Additional file 1: Table S3). Multiple HPV DNA types
were not found in ASCUS, whereas their prevalence was
14.8 % in normal cytology cases (Fig. 5, Additional
file 1: Table S3). In contrast with the similar preva-
lence of single HPV types in neoplastic lesions of different
grades, the prevalence of multiple types increased as the
severity of neoplastic lesions increased from 31.3 % in
LSIL, 39.2 % in HSIL and 57.1 % in CC (Fig. 5, Additional
file 1: Table S3).
HPV types by age group and severity of neoplastic
lesions
The prevalence of HPV-positive cases associated to
LSIL, HSIL and CC increased from the 15–24 years to
Fig. 4 HPV DNA prevalences in neoplastic lesions: overall, HR-HPV types and LR-HPV types. Overall and HR-HPV prevalences increased with the
severity of neoplastic lesions
Fig. 5 Prevalence of single and multiple HPV infections in neoplastic lesions. The prevalence of single infections was highest in ASCUS,
decreased in LSIL and had similar values in HSIL and CC. The prevalence of multiple infections was null in ASCUS and increased
gradually from LSIL to HSIL and CC
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the 25–34 years groups (Fig. 6). In LSIL it increased be-
fore, reaching their maximum value in the 25–34 years
group and then decreasing gradually in the older age
groups (Fig. 6). HPV-positivity in HSIL peaked in the
35–44 years group and declined in older age groups,
whereas in CC it peaked in a plateau spanning the
35–44 and 45–54 years decades and then decreased
slightly in the ≥55 years group (Fig. 6).
The most prevalent HR-HPV types in cases with nor-
mal cytology were HPV33 (18.5 %), HPV16 and HPV51
(11.1 %); in ASCUS the only types detected were HPV33
(13.3 %), and HPV39 and HPV51 (6.7 % each) (Additional
file 1: Table S3).
In LSIL the most prevalent types were HPV33 (39.5 %)
and HPV16 (14.9 %). In HSIL the most prevalent type
was HPV16 (20.3 %), followed by HPV33 (16.3 %) and
HPV39 (11.5 %) (Additional file 1: Table S3). The same
types predominated in CC: HPV16 (47.6 %), HPV33
(38.1 %) and HPV39 (19.0 %). HPV18 ranked fourth in
prevalence in LSIL, HSIL and CC (Additional file 1:
Table S3).
Three prevalence trends as a function of neoplastic
progression were identified among HR-HPV types
(Fig. 7a): 1) increasing (minimum in LSIL, intermediate
in HSIL, maximum in CC) for HPV16, HPV39, HPV18,
HPV58, HPV31, and HPV35; 2) asymptotic (minimum
in LSIL, maximum with similar values in HSIL and CC)
for HPV51 and HPV68; and 3) U-shaped (maximum in
LSIL and CC, minimum in HSIL) only for HPV33. Such
prevalence trends for HPV16, HPV68 and HPV33 are il-
lustrated in Fig. 7b.
The most prevalent LR-HPV types in LSIL were
HPV43 (7.8 %), HPV6/11 (7.2 %) and HPV66 (4.9 %); in
HSIL they were HPV6/11 (13.5 %) and HPV43 =HPV66
(7.4 %); and in CC they were HPV6/11 (14.3 %) and
HPV43 =HPV44 (9.5 %) (Additional file 1: Table S3).
Discussion
This is the first study on the prevalence of cervical infec-
tions by anogenital HR- and LR-HPV types and their as-
sociation with the age and severity of neoplastic lesions
in women subjected to colposcopy in the state of San
Luis Potosí, Mexico. HPV33 appeared to be causing an
outbreak at the time of the study since it was the most
prevalent and the only HR-HPV type with the maximum
association to low-grade neoplastic lesions.
Two-thirds (67.6 %) of the women included in the
study were infected by HPV, a prevalence five to six
times higher than that reported for women in the gen-
eral population of Mexico [22] and other countries [23].
Nearly half of the HPV-positive women (47.9 %) had
multiple infections, with a prevalence value in the upper
end of the range of international studies [24].
In the state of San Luis Potosí circulate all 19 HPV
types identifiable by the nested multiplex PCR method
[18] used in this study. The order of prevalence of the
major HR-HPV types (HPV33 > HPV16 > HPV18 =
HPV58) contrasts with that reported in international
studies (HPV16 > HPV18 > HPV31) [10, 12]. It is espe-
cially striking that in this study HPV33 prevalence dupli-
cates that of HPV16.
The most prevalent LR-HPV types were HPV6/11 >
HPV43 > HPV66. Although the typing method used does
not distinguish HPV6 from HPV11, international and
Mexican studies suggest that HPV6 may be the most
prevalent [25]. The order of prevalence found for HR-
HPV types differs from those described in global and
South and Central America studies [13] as well as in
other Mexican regions [26, 27].
The overall HPV prevalence found by us is higher than
that reported for women of the general population or with
normal cytology, and the age-specific prevalence curve is
U-shaped, as expected, although less pronounced than the
Fig. 6 HPV-positivity in neoplastic lesions by age groups. Prevalences of HPV-positive cases were highest for LSIL in the 25–34 years group, for
HSIL at the 35–44 years group and for CC in the 35–54 years group
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curves found in international studies of the general popu-
lation [28–30]. Both differences are presumably due to the
fact that the women included in this study were not from
the general population but had been previously diagnosed
with cervical neoplastic lesions. The highest prevalence
values at both ends of the U curve correspond to the 15-
24 years (78.0 %) and ≥55 years (69.0 %) groups, and are
similar to those previously found in Mexico [22] and Latin
America [12, 28, 30].
The overall HPV infection determined correlates with
the severity of neoplastic lesions as has been observed in
international studies [13, 31] and in Mexico [26]. The
HPV prevalence found by us in cases without lesions
(29.6 %) is also within the range found in international
studies [23] and in Mexico [22, 26]. Furthermore, the
prevalence of HR-HPV types found by us in CC (90.5 %)
is similar to that of global studies [31] and consistent
with the concept that persistent HR-HPV infection is a
necessary cause for CC [5, 10].
The discordance between the diagnosis of neoplastic
lesion and HPV infection probably derives both from
the cytological overdiagnosis in cases of apparent lesions
without infection (32.4 %) and the lower sensitivity of
cytology and colposcopy in cases of infection without
apparent lesion (29.6 %). These results reinforce the no-
tion that HPV DNA detection is preferable to cytology
as the primary screening test for CC [32, 33].
In this study HPV33 was the most prevalent type in
LSIL, whereas HPV16 is the most prevalent type in sev-
eral multicentric international studies [13]. Moreover,
the order of prevalence found by us in LSIL for HR-
HPV types (HPV33 > HPV16 > HPV56) differs from that
found by Clifford et al. [13] in HSIL and CC (HPV16 >
HPV33 > HPV39), and indicates that HPV16 is also the
most oncogenic type in the state of San Luis Potosí.
A previous study of cervical samples taken between
2004 and 2005 from women of the city of San Luis
Potosí with similar sociodemographic and clinical char-
acteristics to those of the present study found that
HPV16, HPV31 and HPV18 were the predominant high-
risk types [14]. HPV33 prevalence in the capital city
(1.1 %) compared with that of the present study (23.6 %)
Fig. 7 HR-HPV types with increasing, asymptotic and U-shaped prevalence trends for neoplastic lesions of increasing severity. a HR-HPV types
with the three groups of trends (increasing, asymptotic, U-shaped) are placed in the x-axis in descending order of prevalence of the CC cases.
The height of the bars is proportional to the prevalence of each viral type in lesions of increasing severity: LSIL (green), HSIL (blue) and CC (red).
b Examples of prevalence trends of three HR-HPV types as a function of the severity of neoplastic lesions: increasing for HPV16, asymptotic for
HPV68 and U-shaped for HPV33
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corresponds to a 21.4-fold increase and is consistent
with an outbreak that may have originated from several
municipalities located in the middle region of the state
whose average HPV33 prevalence in the present study is
56.2 % (data not shown). Since the severity of cervical
neoplastic lesions progresses as the duration of HPV in-
fections increases, in a steady-state epidemiologic situ-
ation (i.e., with no outbreaks by any viral type) the
prevalence trends of the HR-HPV types as a function of
the severity of neoplastic lesions would be increasing
(i.e., LSIL > HSIL > CC) for the more oncogenic types
and asymptotic for the less oncogenic ones (i.e., LSIL >
HSIL = CC). In the present study both trends were found
for all the HR-HPV types identified except for HPV33,
whose highest prevalence was in LSIL, the most recent
lesions. Besides its predominance, HPV33 was also the
only viral type whose prevalence as a function of the se-
verity of neoplastic lesions was not increasing or asymp-
totic but U-shaped (i.e., higher in LSIL and CC and
minimum in HSIL). Both of these anomalies suggest that
an HPV33 outbreak was taking place during the sam-
pling for the present study.
A recent study performed by Chen et al. [34] in 30
countries discovered new HPV33 variants that were clas-
sified in four phylogenetic groups. We are currently se-
quencing the ORF E6 from HPV33 single infections in
order to identify its circulating variants and to determine
their geographic distribution and network connections.
Current prophylactic vaccines prevent both the infec-
tion and development of neoplastic lesions caused by
the HPV types to which they are directed [35]. They also
induce partial protection lasting six months to three
years against a limited number of HR-HPV types phylo-
genetically related to HPV16 or HPV18 [36]: Cervarix®
against HPV31, HPV33, HPV45 and HPV52, and
Gardasil® against HPV31 [35]. The prevalence of the
circulating HPV types found in this study suggests
that both vaccines could have prevented 23 % of the
infections, as well as 25 % of the HSIL and 62 % of
the CC due to HPV16 and HPV18 among the women
included in the study.
This work is being complemented by the identifica-
tion of the HPV types present in paraffin blocks of CC
specimens to estimate the prevalence and relative onco-
genicity of the HPV types as well as which prophylactic
multivalent vaccines would be most effective in this
region.
Conclusions
Two-thirds of the women referred to colposcopy in San
Luis Potosí, Mexico, were infected by all 19 HPV types
identifiable with the method used. Overall HPV preva-
lence was higher than that expected in the general popu-
lation because the women included in the study had
been shown to have abnormal cytology results. The un-
expected order of prevalence of the major HR-HPV
types was HPV33 > HPV16 > HPV18 = HPV58. HPV33
appeared to be causing an outbreak at the time of the
study because it was the most prevalent and the only
HR-HPV type whose association to LSIL predominated.
The prevalence of the circulating HPV types and their
association to neoplastic lesions suggest that the divalent
and quadrivalent prophylactic anti-HPV vaccines could
have prevented 23 % of the infections as well as 25 % of
the HSIL and 62 % of the CC associated to HPV16 and
HPV18.
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